Skip to content
ChickenStockChickenStock
Research001060
JW Pharmaceutical logo

JW Pharmaceutical (001060) stock

KOSPI · Pharmaceuticals

KRW 23,550-0.42%(-100)

As of Nov 16, 9:14 AM KST

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

5.72x

P/B

1.41x

P/S

0.71x

Earnings

Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.

Quarters and year-to-date
PeriodRevenueOperating profitNet incomeRevenue YoY
Q2 2026Consolidated · Filed Aug 14, 2026KRW 222 billionKRW 33.3 billionKRW 27.9 billion+16.2%
Q1 2026Consolidated · Filed May 15, 2026KRW 199.9 billionKRW 33.6 billionKRW 27.5 billion+7.9%
Q4 2025Consolidated · Filed Mar 18, 2026KRW 198.9 billionKRW 15.5 billionKRW 15.3 billion—
Q3 2025Consolidated · Filed Nov 14, 2025KRW 200 billionKRW 32 billionKRW 30.6 billion+12.0%
Q2 2025Consolidated · Filed Aug 14, 2025KRW 191.1 billionKRW 25 billion-KRW 1.9 billion+10.9%
Q1 2025Consolidated · Filed May 15, 2025KRW 185.2 billionKRW 22 billionKRW 17.5 billion+2.6%
Fiscal years
PeriodRevenueOperating profitNet incomeRevenue YoY
FY2025Consolidated · Filed Mar 18, 2026KRW 775.3 billionKRW 94.5 billionKRW 61.5 billion—
FY2024Consolidated · Filed Mar 18, 2025KRW 719.4 billionKRW 82.5 billionKRW 65 billion—
  • Q2 2026 is computed as H1 2026 minus Q1 2026.
  • Q4 2025 is computed as FY2025 minus 9M 2025.
  • Q3 2025 is computed as 9M 2025 minus H1 2025.
  • Q2 2025 is computed as H1 2025 minus Q1 2025.
Original filing (DART)

Short selling and securities lending

Short sales as a share of trading value, the reported short position and the securities lending balance.

Short-sale share
1.15%
Of trading value on Nov 13, 2026
Short-sale value
KRW 10 million
Previous 20-day average 6.02%
Net short position
19,920 shares
As of Nov 11, 2026 · reported with a two-trading-day lag
Lending balance
523,133 shares
As of Nov 13, 2026 · 2.13% of listed shares
Recent short-sale days
DateShareValue
Nov 13, 20261.15%KRW 10 million
Nov 12, 20263.57%KRW 70 million
Nov 11, 202620.42%KRW 240 million
Nov 10, 20261.80%KRW 20 million
Nov 9, 20267.83%KRW 110 million
Nov 6, 20266.17%KRW 60 million
Nov 5, 202611.21%KRW 190 million
Nov 4, 20265.26%KRW 50 million
Nov 3, 20268.21%KRW 50 million
Nov 2, 202610.47%KRW 60 million

The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.

JW Pharmaceutical (001060) stock information

KOSPI

JW Pharmaceutical (001060) is listed on KOSPI. Its market capitalization is about KRW 578.9 billion. On trailing-twelve-month earnings the P/E ratio is 5.72, and the P/B ratio is 1.41. Return on equity is 24.7%. These figures are computed in-house from official filings and are reference information only.

JW Pharmaceutical — frequently asked questions

What is the P/E ratio of JW Pharmaceutical (001060)?
On a trailing-twelve-month basis, 001060 trades at a P/E ratio of 5.72. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of JW Pharmaceutical?
001060 has a market capitalization of about KRW 578.9 billion. The figure moves with the share price and is refreshed each trading day.
Does JW Pharmaceutical pay a dividend?
001060 has a dividend yield of about 2.76%, based on disclosed payment history. Dividend policy can change; this is reference information only.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.